Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment of systemic sclerosis

J E Pope1

  • 1University of Western Ontario, London, Canada.

Rheumatic Diseases Clinics of North America
|November 1, 1996
PubMed
Summary

Clinical trial guidelines are recommended for progressive systemic sclerosis to assess drug efficacy. Current treatments show limited success for disease modification, but specific symptoms like esophagitis, Raynaud

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2021
Same author

Health Assessment Questionnaire at One Year Predicts All-Cause Mortality in Patients With Early Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2020
Same author

Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort.

ACR open rheumatology·2019
Same author

Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis.

ACR open rheumatology·2019
Same author

Immunoglobulin G<sub>4</sub>-related disease as a mimicker of granulomatosis with polyangiitis: a case report.

Scandinavian journal of rheumatology·2019
Same author

A systematic review of viral exposures as a risk for rheumatoid arthritis.

Seminars in arthritis and rheumatism·2018

Area of Science:

  • Rheumatology
  • Clinical Pharmacology
  • Systemic Sclerosis Research

Background:

  • Progressive systemic sclerosis (PSS) management requires improved methods for evaluating drug efficacy.
  • Past disease-modifying drug trials in scleroderma have yielded disappointing outcomes.
  • Existing treatments offer symptomatic relief for specific PSS complications.

Purpose of the Study:

  • To highlight the need for standardized clinical trial guidelines in PSS.
  • To review current therapeutic approaches for PSS manifestations.
  • To emphasize the importance of evidence-based treatment strategies for scleroderma.

Main Methods:

  • Review of existing literature on clinical trials in progressive systemic sclerosis.
  • Analysis of current treatment outcomes for esophagitis, Raynaud's phenomenon, and scleroderma renal crisis.
  • Identification of knowledge gaps in PSS treatment, particularly for lung involvement.

Main Results:

  • Omeprazole has significantly improved esophagitis treatment.
  • Calcium channel blockers and iloprost are effective for Raynaud's phenomenon.
  • Angiotensin-converting enzyme inhibitors are crucial for managing scleroderma renal crisis.
  • Optimal treatment for rapidly progressive scleroderma lung disease remains undetermined.

Conclusions:

  • Standardized guidelines are essential for future clinical trials in PSS to accurately determine drug efficacy.
  • While symptomatic treatments are available, effective disease-modifying therapies for PSS are still needed.
  • Further research is required to establish best practices for managing severe PSS manifestations, especially lung disease.

Related Experiment Videos